Profile data is unavailable for this security.
About the company
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs: obesity-enobosarm in combination with GLP-1 RA to augment fat loss, to prevent muscle loss, and maintain physical function for higher quality weight loss, and breast cancer-enobosarm plus abemaciclib for the second line treatment of androgen receptor positive, estrogen receptor positive and others. Sabizabulin, a microtubule disruptor, is being developed for the treatment of hospitalized patients with viral-induced ARDS. It also has an FDA-approved commercial product, FC2 Female Condom (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.
- Revenue in USD (TTM)14.09m
- Net income in USD-40.13m
- Incorporated1971
- Employees189.00
- LocationVeru Inc2916 N. MIAMI AVENUE, SUITE 1000MIAMI 33127United StatesUSA
- Phone+1 (312) 595-9123
- Fax+1 (312) 595-9122
- Websitehttps://verupharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXIL Brands Inc | 27.24m | 3.07m | 26.31m | 14.00 | 17.49 | 3.34 | 14.19 | 0.9658 | 0.2328 | 0.2328 | 2.08 | 1.22 | 2.45 | 2.82 | 51.64 | 1,945,967.00 | 15.64 | 16.42 | 22.09 | 23.89 | 72.31 | 73.17 | 6.38 | 5.67 | 1.65 | -- | 0.018 | -- | 16.91 | 94.31 | 82.66 | -- | 62.06 | -- |
| KP Tissue Inc | 0.00 | 4.56m | 59.08m | -- | 12.94 | 1.17 | 12.96 | -- | 0.6393 | 0.6393 | 0.00 | 7.08 | 0.00 | -- | -- | -- | 8.65 | -5.57 | 8.89 | -5.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 51.83 | -- | -- | 0.00 |
| Veru Inc | 14.09m | -40.13m | 98.81m | 189.00 | -- | 2.63 | -- | 7.01 | -0.346 | -0.346 | 0.1166 | 0.257 | 0.2222 | 1.64 | 4.19 | 74,560.37 | -63.27 | -42.91 | -90.64 | -54.41 | 33.41 | 72.41 | -284.76 | -104.96 | 3.16 | -- | 0.2027 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| Big Tree Cloud Holdings Ltd | 0.00 | 75.52k | 130.71m | -- | -- | 0.3688 | 1,730.86 | -- | -0.0109 | -0.0109 | 0.00 | 6.21 | 0.00 | -- | -- | -- | 0.1582 | -- | 0.1632 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | 506.54 | -- | -- | -- |
| Beauty Health Co | 347.62m | -28.17m | 176.11m | 881.00 | -- | 2.95 | 35.82 | 0.5066 | -0.2244 | -0.2244 | 2.78 | 0.4812 | 0.4157 | 1.81 | 6.74 | 394,574.30 | -3.37 | -- | -3.83 | -- | 61.43 | -- | -8.10 | -- | 5.57 | -- | 0.9023 | -- | 8.78 | -- | -326.38 | -- | -- | -- |
| Nu Skin Enterprises, Inc. | 1.78bn | -103.21m | 358.91m | 3.70k | -- | 0.5076 | -- | 0.2022 | -2.08 | -2.08 | 35.33 | 14.22 | 1.05 | 1.93 | 24.31 | 479,776.20 | -6.11 | 6.80 | -7.93 | 8.90 | 70.70 | 73.45 | -5.81 | 5.26 | 1.20 | 4.09 | 0.3801 | 62.58 | -11.53 | -5.97 | -91.80 | -41.16 | -3.63 | 1.33 |
| Yatsen Holding Ltd - ADR | 463.56m | -122.82m | 453.08m | 1.51k | -- | 0.8965 | -- | 0.9774 | -5.27 | -5.27 | 11.10 | 5.03 | 0.6388 | 2.07 | 18.59 | 308,010.30 | -17.17 | -21.94 | -20.10 | -26.50 | 74.83 | 67.11 | -26.88 | -27.00 | 3.71 | -- | 0.00 | -- | -7.86 | 39.98 | 8.29 | -- | 55.24 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Sep 2024 | 7.86m | 5.37% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.55m | 5.16% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 7.28m | 4.98% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.97m | 4.08% |
| Millennium Management LLCas of 30 Sep 2024 | 5.55m | 3.80% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.94m | 2.01% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 2.83m | 1.93% |
| Rosalind Advisors, Inc.as of 30 Sep 2024 | 2.69m | 1.84% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.07m | 1.42% |
| Altium Capital Management LPas of 30 Sep 2024 | 2.03m | 1.39% |
